Imatinib and its successors - How modern chemistry has changed drug development

Current Pharmaceutical Design

Volumn 15, Issue 2, 2009, Pages 120-133

  Müller, Bernhard A ^a  

^a UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

Author keywords

Aurora kinase; BCR ABL; CML; Imatinib; SGX393; Tyrosine kinase inhibitor

Indexed keywords

4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; \PHA 680632; ALPHA INTERFERON; ANTINEOPLASTIC ANTIMETABOLITE; AURORA KINASE INHIBITOR; BAFETINIB; BCR ABL PROTEIN; BOSUTINIB; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTARABINE; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FINGOLIMOD; FLUOROBENZAMIDE; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NILOTINIB; PHA 680632; PHA 739358; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; SGX 393; UNCLASSIFIED DRUG; US 20070004734; 4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; AURORA KINASE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; THIAZOLE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CARCINOGENESIS; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DOSE RESPONSE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; FLUID RETENTION; HIGH THROUGHPUT SCREENING; HUMAN; LONG QT SYNDROME; MONOTHERAPY; NAUSEA; NONHUMAN; PATENT; PLEURA EFFUSION; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG DEVELOPMENT; ENZYMOLOGY; HISTORY; METHODOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HISTORY, 20TH CENTURY; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 61549138378     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787002933     Document Type: Review

References (70)

1. Gram HC. Über die isolierte farbung der schizomyceten in schnittund trockenpraparaten. Fortschritte der Medizin 1884; 2: 185-89.
2. Gilman A, Philips FS. The biological actions and therapeutic applications of β-chloroethyl amines and sulfides. Science 1946; 103: 409-15.
3. Neidle S, Thurston DE. Chemical approaches to the discovery and development of cancer therapies. Nat Rev Cancer 2005; 5: 285-96.
4. Dresler WF, Stein R. Über den hydroxhylarnstoff. Justus Liebigs Ann Chem Pharm 1869; 150: 242-52.
5. Rosenthal F, Wislicki L, Kollek L. Über die Beziehungen von schwersten blutgiften zu abbauproducten des eiweisses: Ein beitrag zum einstehungsmechanismus der perniziösen anämie. Klin Wochenschr 1928; 7: 972-7.
6. King SB. The nitric oxide producing reactions of hydroxyurea. Curr Med Chem 2003; 10: 437-52.
7. Plucinski TM, Fager RS, Reddy GP. Allosteric interaction of components of the replitase complex is responsible for enzyme cross-inhibition. Mol Pharmacol 1990; 38: 114-20.
8. Reddy GP, Pardee AB. Multienzyme complex for metabolic channeling in mammalian DNA replication. Proc Natl Acad Sci USA 1980; 77: 3312-6.
9. Newton HB. Hydroxyurea chemotherapy in the treatment of meningiomas. Neurosurg Focus 2007; 23: E11.
10. Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, et al. Targeted therapies for cancer. Am J Clin Pathol 2004; 122: 598-609.
11. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 1997; 23: 3-25
12. Savage DG, Szydlo RM, Goldmann JM. Clinical features at the diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol 1997; 96: 111-6.
13. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004; 103: 4010-22.
14. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukaemia cells selected for resistance to STI571. Blood 2003; 101: 690-8.
15. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukemia. Nat Rev Cancer 2007; 7: 345-56.
16. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, Imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1: 493-502.
17. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-6.
18. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, et al. Dynamics of chronic myeloid leukemia. Nature 2005; 435: 1267-70.
19. Goldman JM, Hughes T, Radich J, Branford S, Hochhaus A, Charlene S, et al. Continuing reduction in level of residual disease after 4 years in patients with CML in chronic phase responding to first-line Imatinib in the IRIS study. Blood 2005; 106: 51a. Abstract 163.
20. de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26: 3358-63.
21. O'Brian S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, et al. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer 2003; 98: 888-93
22. Tipping AJ, Mahon FX, Zafiridis G, Lagarde V, Goldman JM, Melo JV. Drug response of imatinib mesylate-resistant cells. Synergism of imatinib with other chemotherapeutic drugs. Leukemia 2002; 16: 2349-57.
23. Mello JV, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett 2007; 249: 121-32.
24. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117-25.
25. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as therapeutic agent for chronic myeloid leukaemia. Blood 2005; 105: 2640-53.
26. La Rosée P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res 2002; 62: 7149-53.
27. Kimura S. Second generation Abl kinase inhibitors and novel compounds to eliminate the Bcr-Abl/T315I clone. Recent Patents Anticancer Drug Discov 2006; 1: 347-55.
28. Cowan-Jacob SW, Fendrich G, Floersheimer A, Furet P, Liebetanz J, Rummel G, et al. Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta Crystallogr D Biol Crystallogr 2007; D63: 80-93.
29. According to: http://www.fda.gov/bbs/topics/NEWS/2007/ NEW01734.html [accessed: August 18, 2008].
30. le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008; 111: 1834-9.
31. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542-51.
32. Jabbour E, El Ahdab S, Cortes J, Kantarjian H. A novel BCR-ABL tyrosine kinase inhibitor for the treatment of leukemias. Expert Opin Investig Drugs 2008; 17: 1127-36.
33. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002; 62: 4236-43.
34. Asaki T, Sugiyama Y, Hamamoto T, Higashioka M, Umehara M, Naito H, et al. Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors. Bioorg Med Chem Lett 2006; 16: 1421-5.
35. Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008; 49: 615-9.
36. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658-61.
37. Wityak J, Das J, Moquin RV, Shen Z, Lin J, Chen P, et al. Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56lck. Bioorg Med Chem Lett 2003; 13: 4007-10.
38. US Pat. Appl. Publ., 2006004067
39. Veach DR, Namavari M, Pillarsetty N, Santos EB, Beresten-Kochetkov T, Lambek C, et al. Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib. J Med Chem 2007; 50: 5853-7.
40. Hantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M, Schutze G, et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 2007; 104: 13283-88.
41. Nguyen TK, Rahmani M, Harada H, Det P, Grant S. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukaemia cells to the dual Abl/Scr inhibitor BMS-345825. Blood 2007; 109: 4006-15.
42. Boschelli DH. 4-anilino-3-quinolinecarbonitriles: An emerging class of kinase inhibitors. Curr Top Med Chem 2002; 9: 1051-63.
43. Boschelli DH. Exploitation of the 3-quinolinecarbonitrile template for Scr tyrosine kinase inhibitors. Curr Top Med Chem 2008; 8: 922-34.
44. Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant BCR-Abl+ neoplastic cells. Cancer Res 2006; 66: 11314-22.
45. Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Scr and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukaemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003; 63: 375-81.
46. According to: http://www.medscape.com/viewarticle/576109 [accessed: August 18, 2008].
47. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004; 4: 927-36.
48. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003; 4: 842-54.
49. Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, et al. Inhibition of drug-resistant mutants of ABL, KIT, EGF receptor kinases. Proc Natl Acad Sci USA 2005; 102: 11011-6.
50. Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH 3rd, et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 2006; 66: 1007-14.
51. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ, et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007; 109: 500-2.
52. According to: http://kinasepro.wordpress.com/2006/11/21/2. [accessed: August 18, 2008].
53. Fancelli D, Moll J, Varasi M, Bravo R, Artico R, Berta D, et al. 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: Identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition. J Med Chem 2006; 49: 7247-51.
54. Fancelli D, Berta D, Bindi S, Cameron A, Cappella P, Carpinelli P, et al. Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem 2005; 48: 3080-4.
55. Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, et al. Simultaneous targeting of Aurora kinases and Bcr-Abl by the small molecule inhibitor PHA-739358 is effective in Imatinib-resistant mutations including T315I. Blood 2008; 111: 4355-64.
56. Modugno M, Casale E, Soncini C, Rosettani P, Colombo R, Lupi R, et al. Crystal structure of the T315I Abl mutant in complex with the aurora kinase inhibitor PHA-739358 Cancer Res 2007; 67: 7987-90.
57. O'Hare T, Eide CA, Tyner JW, Corbin AS, Wong MJ, Buchanan S, et al. SGX393 inhibits the CML mutant BCR-ABLT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc Natl Acad Sci USA 2008; 105: 5507-12.
58. Dumont FJ. Fingolimod. IDrugs 2005; 8: 236-53.
59. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome - positive acute lymphocytic leukemia. J Clin Invest 2007; 117: 2408-21.
60. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005; 8: 355-68.
61. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, et al. The immune modulator FTY720 targets phingosine 1-phosphate receptors. J Biol Chem 2002; 277: 21453-7.
62. Fresno M, Jimenez A, Vasquez D. Inhibition of translation in eukaryotic systems by harringtonine. Eur J Biochem 1977; 72: 323-30.
63. Yinjun L, Jie J, Weilai X, Xiangming T. Homoharringtonine mediates myeloid cell apoptosis via upregulation of proapoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP). Am J Hematol 2004; 76: 199-204.
64. O'Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995; 86: 3322-6.
65. Quintas-Cardama A, Cortes J. Omacetaxine mepesuccinate - a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies. IDrugs 2008; 11: 356-72.
66. Cheng JC, Zhang JH, Zhang QB, Yang J, Huang L. Stereospecific synthesis of deoxyharringtonine and homoharringtonine. Yao Xue Xue Bao 1984; 19: 178-83.
67. Tong H, Ren Y, Zhang F, Jin J. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells. Eur J Haematol 2008; 81: 259-66.
68. Barbarotto E, Calin GA. Potential therapeutic applications of miRNA-based technology in hematological malignancies. Curr Pharm Des 2008; 14(21): 2040-50.
69. Puttini M, Redaelli S, Moretti L, Brussolo S, Gunby RH, Mologni L, et al. Characterization of compound 584, an Abl kinase inhibitor with lasting effects. Haematologica 2008; 93(5): 653-61.
70. Vajpai N, Strauss A, Fendrich G, Cowan-Jacob SW, Manley PW, Grzesiek S, et al. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem 2008; 283(26): 18292-302.